DURHAM, N.C., Aug. 26, 2013 /PRNewswire/ -- Novan Therapeutics announced today that the U.S. Department of Health and Human Services has entered into a contract with Novan to advance the development of a nitric oxide-based therapy as a topical treatment for thermal burns. The Biomedical Advanced Research and Development Authority (BARDA), an agency within the Office of the Assistant Secretary for Preparedness and Response, awarded this contract. It is widely believed a mass casualty event caused by natural or intentional threats to public health could result in tens of thousands of burn patients which would overwhelm the burn care infrastructure presently available in hospitals across the United States.
Under the terms of the contract, BARDA will provide funding of $7.8 million over two years. The contract will support the pharmaceutical development of the Nitric Oxide Advanced Healing (NOAH) technology including formulation work, nonclinical toxicology, and proof of concept studies in models of deep partial thickness and full thickness thermal injuries. This project is designed to enable the future clinical investigation of the medical countermeasure.
"We are honored that BARDA selected our team to develop a nitric oxide therapy for thermal burns," said Nathan Stasko, president of Novan. Nitric oxide, a molecule produced by the human body, has been demonstrated throughout peer-reviewed literature to speed the migration of epidermal cells, stimulate new blood vessel growth, modulate inflammation, and re-model the wound bed. Dr. Stasko continued, "The link between nitric oxide and the body's ability to heal is well established. The challenge is to create stable nitric oxide drugs that 'perform on com
|SOURCE Novan Therapeutics|
Copyright©2012 PR Newswire.
All rights reserved